NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, HONG KONG, SINGAPORE, SOUTH AFRICA, SWITZERLAND OR THE UNITED STATES OR IN ANY JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
The Sobi AGM convened earlier today in Stockholm and voted in favour of all resolutions proposed at the meeting, including: Adoption of the profit and loss statements and balance sheets, and discharge of liability The AGM adopted the Profit and Loss statements and Balance Sheets and approved the proposal to carry forward the retained profits of SEK 3,458,079,130. The AGM discharged the members of the Board and the CEO from liability for the financial year 2010. Election of Board of Directors, remuneration to the Directors and election of Auditor The ordinary Board members Adine Grate Axén, Bo Jesper Hansen, Lennart Johansson and Hans Wigzell were re-elected Board members and Helena Saxon and Hans GCP Schikan were elected new Board members. Bo Jesper Hansen was re-elected chairman of the Board. Hans Glemstedt, Wenche Rolfsen and Michael Steinmetz had declined re-election. The AGM approved the Nomination Committee's proposal regarding remuneration to the Board. PricewaterhouseCoopers AB was re-elected auditor of Sobi until the end of the Annual General Meeting 2012. Nomination Committee The AGM approved the proposed instructions and charter for the Nomination Committee. Principles for remuneration for Management, Long-term Incentive program and transfer of own shares The AGM approved the proposed guidelines for remuneration for the management. The AGM further approved the Board's proposal on the implementation of a performance based long-term share program for 2011 ("Share Program 2011"), comprising a resolution regarding amendment of the articles of association, a resolution regarding authorization for the Board to resolve on a directed issue of C-shares and a resolution regarding authorization for the Board to repurchase issued C-shares. The AGM also approved the Board's proposal regarding transfer of own shares to participants in the Share Programs 2008-2011, in accordance with the terms and conditions of the programs, and on transfer of own shares on the stock exchange for the purpose of covering certain payments, primarily social security charges, that may occur in relation to Share Program 2008. Amendments of the Articles of Association and approval of rights issue with preferential rights for shareholders The AGM resolved to amend the limits in the Articles of Association in respect of the share capital to not less than SEK 110,000,000 and not more than SEK 440,000,000 and in respect of the number of shares to not less than 200,000,000 and not more than 800,000,000 shares. The AGM resolved to approve the Board of Directors' resolution on a new issue of common shares with preferential rights for the shareholders. As previously communicated, according to the terms for the rights issue determined by the Board of Directors, each existing share in Sobi entitles to one subscription right and four subscription rights entitle to subscription of one new common share at a subscription price of SEK 12 per share, which means that the rights issue will provide Sobi with not more than approximately SEK 637,000,000 before transaction costs and that the share capital may be increased by not more than approximately SEK 29,105,800. The rights issue is fully covered by subscription undertakings by major shareholders and underwriting undertakings by Carnegie Investment Bank and Svenska Handelsbanken. A prospectus relating to the rights issue will be published around May 5, 2011. Full details on each proposal adopted by the AGM can be downloaded from www.sobi.com . For more information, contact: Åsa Stenqvist, VP Communications and Investor Relations Phone: +46 8 697 20 00 The above information has been made public in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was released for public distribution on 28 April 2011 at 8.45 p.m. CET. IMPORTANT INFORMATION The information in this press release is not intended for distribution, publication or public release, directly or indirectly, in or into Australia, Canada, Hong Kong, Japan, Singapore, South Africa, Switzerland, the United States or any other jurisdiction where the distribution of this press release may be unlawful. The distribution of this announcement may be restricted by law in certain jurisdictions and persons into whose possession any document or other information referred to herein comes should inform themselves about and observe any such restriction. The information in this press release is not an offer to sell or a solicitation to buy shares. This press release is not a prospectus under the Prospectus Directive 2003/71/EC. A prospectus will be prepared and published in accordance with the Prospectus Directive and will thereafter be made available by the Company. Investors shall not subscribe for securities referred to in this press release other than on the basis of the information which will be included in such prospectus. The information in this press release does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 (the "Securities Act"). The securities mentioned herein may not be offered or sold in the United States unless they are registered under the Securities Act or pursuant to an available exemption therefrom.. There will be no public offer of securities in the United States. The information in this press release may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Any forwarding, distribution, reproduction, or disclosure of this information in whole or in part may be prohibited. Failure to comply with these instructions may result in a violation of the Securities Act or the applicable laws of other jurisdictions. This press release may contain forward-looking statements. Words such as "expect", "believe", "estimate", "plan" and "forecast" in this press release are intended to indicate forward-looking statements. These forward looking statements reflect the current expectations on future events of the management at the time such statements are made, but are made subject to risks and uncertainties. All these forward-looking statements are based on the expectations and assumptions of the management and are deemed reasonable but uncertain and difficult to predict. Actual outcomes and results may differ significantly from the forward looking statements. The Company does not intend, nor undertakes, to update any such forward looking statements.
We are a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases.
Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care.
We contribute to societies by improving access to treatment of rare diseases.
Find out more about our business and financial performance.
Here we present our most recent press releases, news articles, and images.
Every day, we work actively to find better ways to understand and meet patient needs.